Tirdzniecība FibroGen, Inc - FGEN CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.10 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.025457% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | 0.003235% | ||||||||
| Nakts laika nodeva | 21:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
FibroGen Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 17.04 |
| Atvērt* | 17.16 |
| Izmaiņas par 1 gadu* | 71.94% |
| Dienas Diapazons* | 16.94 - 17.31 |
| 52 ned Diapazons | 8.67-25.69 |
| Vidējais apjoms (10 dienas) | 784.84K |
| Vidējais apjoms (3 mēneši) | 19.37M |
| Tirgus Kapitalizācija | 1.63B |
| Cenas/Peļņas Attiecība | -100.00K |
| Izvietotās Akcijas | 97.58M |
| Ieņēmumi | 116.07M |
| EPS | -3.27 |
| Dividende (Ienesīgums %) | N/A |
| Beta | 0.78 |
| Nākamās Peļņas Datums | Aug 7, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| May 30, 2023 | 17.04 | 0.47 | 2.84% | 16.57 | 17.33 | 16.46 |
| May 26, 2023 | 16.65 | 0.03 | 0.18% | 16.62 | 16.80 | 16.33 |
| May 25, 2023 | 16.82 | 0.16 | 0.96% | 16.66 | 16.91 | 16.44 |
| May 24, 2023 | 16.90 | -0.05 | -0.29% | 16.95 | 17.33 | 16.51 |
| May 23, 2023 | 17.27 | 0.06 | 0.35% | 17.21 | 18.03 | 16.99 |
| May 22, 2023 | 17.16 | -0.14 | -0.81% | 17.30 | 18.02 | 16.96 |
| May 19, 2023 | 17.49 | -0.07 | -0.40% | 17.56 | 18.07 | 17.20 |
| May 18, 2023 | 17.53 | 0.01 | 0.06% | 17.52 | 17.89 | 17.29 |
| May 17, 2023 | 17.77 | 0.80 | 4.71% | 16.97 | 17.86 | 16.92 |
| May 16, 2023 | 17.40 | 0.25 | 1.46% | 17.15 | 17.51 | 17.08 |
| May 15, 2023 | 17.58 | 0.46 | 2.69% | 17.12 | 17.91 | 17.03 |
| May 12, 2023 | 17.31 | -0.11 | -0.63% | 17.42 | 17.66 | 17.09 |
| May 11, 2023 | 17.48 | -0.12 | -0.68% | 17.60 | 18.00 | 17.38 |
| May 10, 2023 | 17.65 | 0.25 | 1.44% | 17.40 | 17.84 | 17.17 |
| May 9, 2023 | 17.30 | 1.25 | 7.79% | 16.05 | 17.89 | 15.97 |
| May 8, 2023 | 17.61 | 0.58 | 3.41% | 17.03 | 17.73 | 16.55 |
| May 5, 2023 | 17.29 | 1.14 | 7.06% | 16.15 | 17.55 | 15.83 |
| May 4, 2023 | 16.68 | 0.36 | 2.21% | 16.32 | 16.85 | 15.93 |
| May 3, 2023 | 16.52 | 0.48 | 2.99% | 16.04 | 17.04 | 15.95 |
| May 2, 2023 | 16.06 | -0.12 | -0.74% | 16.18 | 16.55 | 15.93 |
FibroGen, Inc Events
| Laiks (UTC) (UTC) | Valsts | Notikums |
|---|---|---|
| Wednesday, June 7, 2023 | ||
| Laiks (UTC) (UTC) 15:00 | Valsts US
| Notikums FibroGen Inc Annual Shareholders Meeting FibroGen Inc Annual Shareholders MeetingForecast -Previous - |
| Friday, June 16, 2023 | ||
| Laiks (UTC) (UTC) 15:00 | Valsts US
| Notikums FibroGen Inc Annual Shareholders Meeting FibroGen Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, August 7, 2023 | ||
| Laiks (UTC) (UTC) 10:59 | Valsts US
| Notikums Q2 2023 FibroGen Inc Earnings Release Q2 2023 FibroGen Inc Earnings ReleaseForecast -Previous - |
| Monday, November 6, 2023 | ||
| Laiks (UTC) (UTC) 10:59 | Valsts US
| Notikums Q3 2023 FibroGen Inc Earnings Release Q3 2023 FibroGen Inc Earnings ReleaseForecast -Previous - |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 140.734 | 235.309 | 176.319 | 256.577 | 212.958 |
| Ienākumi | 140.734 | 235.309 | 176.319 | 256.577 | 212.958 |
| Kopējie Darbības Izdevumi | 441.759 | 523.839 | 368.199 | 345.891 | 299.651 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 127.474 | 120.557 | 97.238 | 126.557 | 63.812 |
| Pētniecība un Attīstība | 296.791 | 387.043 | 252.924 | 209.265 | 235.839 |
| Darbības Izdevumi | -301.025 | -288.53 | -191.88 | -89.314 | -86.693 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 6.156 | -2.153 | 3.151 | 12.672 | 0.577 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -294.869 | -290.683 | -188.729 | -76.642 | -86.116 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -295.227 | -291.03 | -189.089 | -76.97 | -86.42 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Neto Ienākumi | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Atšķaidītie Neto Ienākumi | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Atšķaidītie Ienākumi par Akcijām | 93.582 | 92.349 | 89.854 | 86.633 | 84.062 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -3.13793 | -3.14051 | -2.10665 | -0.88846 | -1.02805 |
| Atšķaidītā Normalizētā Peļņa par Akciju | -3.13793 | -3.14051 | -2.10665 | -0.88846 | -1.02805 |
| Ārkārtas Posteņi Kopā | |||||
| Cost of Revenue, Total | 20.28 | 12.871 | 8.869 | 1.147 | |
| Bruto Peļņa | 120.454 | 222.438 | 167.45 | 255.43 | |
| Depreciation / Amortization | 0.587 | 4.639 | 10.369 | 10.307 | |
| Other Operating Expenses, Total | -3.373 | -1.271 | -1.201 | -1.385 | |
| Equity In Affiliates | 1.573 | 1.007 | -0.202 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 36.161 | 34.367 | 15.735 | 29.806 | 60.827 |
| Ienākumi | 36.161 | 34.367 | 15.735 | 29.806 | 60.827 |
| Cost of Revenue, Total | 3.491 | 4.925 | 4.308 | 6.809 | 4.238 |
| Bruto Peļņa | 32.67 | 29.442 | 11.427 | 22.997 | 56.589 |
| Kopējie Darbības Izdevumi | 112.252 | 100.519 | 109.392 | 108.03 | 123.82 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 34.275 | 33.966 | 29.902 | 30.258 | 30.564 |
| Pētniecība un Attīstība | 74.486 | 61.628 | 75.182 | 70.963 | 89.018 |
| Other Operating Expenses, Total | |||||
| Darbības Izdevumi | -76.091 | -66.152 | -93.657 | -78.224 | -62.993 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -1.336 | -0.195 | 1.714 | 5.058 | -0.419 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -77.427 | -66.347 | -91.943 | -73.166 | -63.412 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -77.501 | -66.455 | -92.057 | -73.189 | -63.525 |
| Equity In Affiliates | 0.796 | 0.28 | 0.407 | 0.565 | 0.32 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Neto Ienākumi | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Atšķaidītie Neto Ienākumi | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Atšķaidītie Ienākumi par Akcijām | 94.691 | 94.035 | 93.767 | 93.475 | 93.043 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.81006 | -0.70373 | -0.97742 | -0.77694 | -0.67931 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Atšķaidītā Normalizētā Peļņa par Akciju | -0.81006 | -0.70373 | -0.97742 | -0.77694 | -0.67931 |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 492.826 | 474.059 | 755.11 | 702.49 | 690.015 |
| Nauda un Īstermiņa Ieguldījumi | 422.008 | 405.19 | 686.537 | 533.757 | 621.402 |
| Cash | 135.819 | 111.422 | 88.046 | 40.715 | 38.783 |
| Nauda un Ekvivalenti | 19.881 | 59.801 | 590.347 | 85.551 | 50.475 |
| Īstermiņa Ieguldījumi | 266.308 | 233.967 | 8.144 | 407.491 | 532.144 |
| Debitoru Parādu Kopsumma, Neto | 16.299 | 25.401 | 41.883 | 153.665 | 63.684 |
| Accounts Receivable - Trade, Net | 28.387 | 36.331 | 46.01 | 158.51 | 16.474 |
| Prepaid Expenses | 9.73 | 7.383 | 8.353 | 6.464 | 4.929 |
| Total Assets | 610.087 | 773.821 | 826.84 | 857.397 | 880.598 |
| Property/Plant/Equipment, Total - Net | 100.933 | 120.15 | 65.296 | 84.276 | 127.198 |
| Property/Plant/Equipment, Total - Gross | 253.644 | 252.362 | 199.305 | 195.752 | 192.397 |
| Accumulated Depreciation, Total | -152.711 | -132.212 | -134.009 | -111.476 | -65.199 |
| Long Term Investments | 9.409 | 171.621 | 2.972 | 61.118 | 55.82 |
| Other Long Term Assets, Total | 6.919 | 7.991 | 3.462 | 9.513 | 7.565 |
| Total Current Liabilities | 273.562 | 225.497 | 163.187 | 102.745 | 89.033 |
| Accounts Payable | 30.758 | 26.097 | 24.789 | 6.088 | 9.139 |
| Accrued Expenses | 229.639 | 180.356 | 104.384 | 83.816 | 66.123 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 13.129 | 19.033 | 21.684 | 0.49 | 13.771 |
| Total Liabilities | 631.534 | 564.675 | 404.662 | 341.262 | 371.399 |
| Total Long Term Debt | 17.054 | 17.616 | 44.088 | 55.531 | 113.955 |
| Long Term Debt | 16.917 | 17.613 | 18.697 | 16.78 | 16.798 |
| Capital Lease Obligations | 0.137 | 0.003 | 25.391 | 38.751 | 97.157 |
| Minority Interest | 19.967 | 19.967 | 19.271 | 19.271 | 19.271 |
| Other Liabilities, Total | 320.951 | 292.403 | 169.441 | 163.715 | 149.14 |
| Total Equity | -21.447 | 209.146 | 422.178 | 516.135 | 509.199 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.942 | 0.929 | 0.914 | 0.877 | 0.854 |
| Additional Paid-In Capital | 1541.02 | 1476.41 | 1399.77 | 1300.72 | 1226.45 |
| Retained Earnings (Accumulated Deficit) | -1557.69 | -1264.03 | -974.011 | -784.72 | -715.827 |
| Other Equity, Total | -5.72 | -4.163 | -4.499 | -0.747 | -2.281 |
| Total Liabilities & Shareholders’ Equity | 610.087 | 773.821 | 826.84 | 857.397 | 880.598 |
| Total Common Shares Outstanding | 94.1661 | 92.881 | 91.441 | 87.657 | 85.432 |
| Total Inventory | 40.436 | 31.015 | 16.53 | 6.887 | |
| Other Current Assets, Total | 4.353 | 5.07 | 1.807 | 1.717 | |
| Current Port. of LT Debt/Capital Leases | 0.036 | 0.011 | 12.33 | 12.351 | |
| Deferred Income Tax | 9.192 | 8.675 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 430.549 | 492.826 | 474.224 | 520.643 | 524.415 |
| Nauda un Īstermiņa Ieguldījumi | 355.949 | 422.008 | 408.52 | 438.133 | 428.075 |
| Cash | 145.81 | 135.819 | 104.509 | 128.152 | 165.436 |
| Nauda un Ekvivalenti | 42.74 | 19.881 | 51.451 | 39.606 | 20.46 |
| Īstermiņa Ieguldījumi | 167.399 | 266.308 | 252.56 | 270.375 | 242.179 |
| Debitoru Parādu Kopsumma, Neto | 17.654 | 16.299 | 15.328 | 33.573 | 43.883 |
| Accounts Receivable - Trade, Net | 29.217 | 28.387 | 29.665 | 60.352 | 82.638 |
| Total Inventory | 42.456 | 40.436 | 39.95 | 40.899 | 43.067 |
| Prepaid Expenses | 14.49 | 9.73 | 10.426 | 8.038 | 9.39 |
| Other Current Assets, Total | 4.353 | ||||
| Total Assets | 538.544 | 610.087 | 608.837 | 686.789 | 745.934 |
| Property/Plant/Equipment, Total - Net | 95.367 | 100.933 | 105.19 | 109.159 | 114.871 |
| Property/Plant/Equipment, Total - Gross | 253.644 | ||||
| Accumulated Depreciation, Total | -152.711 | ||||
| Long Term Investments | 5.884 | 9.409 | 22.411 | 50.414 | 97.643 |
| Other Long Term Assets, Total | 6.744 | 6.919 | 7.012 | 6.573 | 9.005 |
| Total Current Liabilities | 254.746 | 273.562 | 251.994 | 240.34 | 255.374 |
| Accounts Payable | 71.282 | 30.758 | 19.323 | 29.36 | 36.353 |
| Accrued Expenses | 166.969 | 229.639 | 224.577 | 202.681 | 211.518 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.036 | ||||
| Other Current Liabilities, Total | 16.495 | 13.129 | 8.094 | 8.299 | 7.503 |
| Total Liabilities | 587.396 | 631.534 | 582.531 | 583.009 | 587.886 |
| Total Long Term Debt | 17.276 | 17.054 | 15.422 | 16.439 | 17.374 |
| Long Term Debt | 17.276 | 16.917 | 15.422 | 16.439 | 17.374 |
| Capital Lease Obligations | 0.137 | ||||
| Deferred Income Tax | |||||
| Minority Interest | 19.967 | 19.967 | 19.967 | 19.967 | 19.967 |
| Other Liabilities, Total | 295.407 | 320.951 | 295.148 | 306.263 | 295.171 |
| Total Equity | -48.852 | -21.447 | 26.306 | 103.78 | 158.048 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Common Stock | 0.966 | 0.942 | 0.939 | 0.937 | 0.933 |
| Additional Paid-In Capital | 1589.15 | 1541.02 | 1524.23 | 1509.64 | 1490.86 |
| Retained Earnings (Accumulated Deficit) | -1634.39 | -1557.69 | -1491.51 | -1399.86 | -1327.24 |
| Other Equity, Total | -4.57 | -5.72 | -7.346 | -6.93 | -6.505 |
| Total Liabilities & Shareholders’ Equity | 538.544 | 610.087 | 608.837 | 686.789 | 745.934 |
| Total Common Shares Outstanding | 96.623 | 94.1661 | 93.936 | 93.733 | 93.289 |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Nauda no Darbības | -145.933 | -82.232 | 81.602 | -78.705 | -76.144 |
| Nauda no Darbības | 10.604 | 14.809 | 22.047 | 21.454 | 6.562 |
| Bezskaidras Naudas Preces | 66.687 | 132.899 | 74.216 | 62.47 | 52.112 |
| Samaksātie Procenti Naudā | 0.104 | 0.094 | 0.135 | 0.174 | 0.218 |
| Izmaiņas Apgrozāmajā Kapitālā | 70.43 | 60.083 | 174.63 | -85.659 | -48.398 |
| Nauda no Ieguldījumu Darbībām | 89.116 | -426.972 | 452.487 | 120.018 | -522.123 |
| Kapitālie Izdevumi | -38.741 | -30.186 | -3.994 | -5.762 | -8.02 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | 127.857 | -396.786 | 456.481 | 125.78 | -514.103 |
| Nauda no Darbībām ar Finansēšanu | 46.776 | -0.563 | 13.343 | -4.3 | 13.875 |
| Naudas Plūsma Finansēšanas Posteņos | -6.62 | -7.372 | -11.463 | -12.75 | -15.612 |
| Akciju Izsniegšana (Atkāpšanās), Neto | 53.934 | 12.701 | 37.829 | 20.778 | 29.847 |
| Parādu Izsniegšana (Atkāpšanās), Neto | -0.538 | -5.892 | -13.023 | -12.328 | -0.36 |
| Ārvalstu Valūtas Ietekme | -5.482 | 2.597 | 4.695 | -0.005 | -0.008 |
| Neto Izmaiņas Naudā | -15.523 | -507.17 | 552.127 | 37.008 | -584.4 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -76.705 | -293.654 | -227.479 | -135.829 | -63.205 |
| Cash From Operating Activities | -101.591 | -145.933 | -93.42 | -41.54 | -8.476 |
| Cash From Operating Activities | 2.965 | 10.604 | 7.914 | 5.235 | 2.584 |
| Non-Cash Items | 18.148 | 66.687 | 49.928 | 34.441 | 17.77 |
| Changes in Working Capital | -45.999 | 70.43 | 76.217 | 54.613 | 34.375 |
| Cash From Investing Activities | 103.482 | 89.116 | 88.023 | 43.24 | 25.935 |
| Capital Expenditures | -0.591 | -38.741 | -38.408 | -37.543 | -36.638 |
| Other Investing Cash Flow Items, Total | 104.073 | 127.857 | 126.431 | 80.783 | 62.573 |
| Cash From Financing Activities | 31.485 | 46.776 | -1.898 | -0.806 | -2.893 |
| Financing Cash Flow Items | 0 | -6.62 | -4.562 | -3.361 | -2.974 |
| Issuance (Retirement) of Stock, Net | 31.657 | 53.934 | 2.989 | 2.779 | 0.183 |
| Issuance (Retirement) of Debt, Net | -0.172 | -0.538 | -0.325 | -0.224 | -0.102 |
| Foreign Exchange Effects | -0.526 | -5.482 | -7.968 | -4.359 | 0.107 |
| Net Change in Cash | 32.85 | -15.523 | -15.263 | -3.465 | 14.673 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| PRIMECAP Management Company | Investment Advisor | 14.4767 | 14126697 | 231619 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.0286 | 8810326 | -613439 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.2737 | 6122003 | 89685 | 2023-03-31 | LOW |
| Astellas Pharma Inc | Corporation | 5.0915 | 4968367 | 0 | 2023-01-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.1772 | 4076167 | -188810 | 2023-03-31 | LOW |
| Point72 Asset Management, L.P. | Hedge Fund | 3.5113 | 3426427 | -1355218 | 2023-03-31 | LOW |
| First Trust Advisors L.P. | Investment Advisor | 2.7884 | 2720975 | -254678 | 2023-03-31 | LOW |
| Baker Bros. Advisors LP | Hedge Fund | 2.7027 | 2637384 | 1262173 | 2023-03-31 | LOW |
| Armistice Capital LLC | Hedge Fund | 2.3693 | 2312000 | -1552000 | 2023-03-31 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.7703 | 1727545 | 70450 | 2023-03-31 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 1.7676 | 1724909 | 512435 | 2023-03-31 | HIGH |
| Schroder Investment Management North America Inc. | Investment Advisor | 1.5138 | 1477161 | -246616 | 2023-03-31 | LOW |
| Artisan Partners Limited Partnership | Investment Advisor | 1.3847 | 1351230 | 1351230 | 2023-03-31 | LOW |
| Assenagon Asset Management S.A. | Investment Advisor | 1.3779 | 1344583 | 1344583 | 2023-03-31 | HIGH |
| Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 1.1877 | 1159027 | -348288 | 2023-03-31 | MED |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 1.1157 | 1088768 | 593915 | 2023-03-31 | LOW |
| Eventide Asset Management, LLC | Investment Advisor | 0.9838 | 960000 | 960000 | 2023-03-31 | MED |
| Nuveen LLC | Pension Fund | 0.9185 | 896293 | 328958 | 2023-03-31 | LOW |
| Adage Capital Management, L.P. | Hedge Fund | 0.8711 | 850000 | -1800000 | 2023-03-31 | LOW |
| Eagle Asset Management, Inc. | Investment Advisor/Hedge Fund | 0.8488 | 828307 | -74825 | 2023-03-31 | LOW |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group530K+
Tirgotāji
87K+
Ikmēneša aktīvie klienti
$46M+
Ikmēneša ieguldījumu apjoms
$31M+
Izņemts katru mēnesi
Treidinga kalkulators
Aprēķiniet iespējamo peļņu un zaudējumus, uzsākot CFD darījumu noteiktā dienā (izvēlaties datumu) un slēdzot darījumu citā dienā (izvēlaties datumu).
Tirdzniecības komisija
0
- 1:1
Finanšu svira
1:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
FibroGen, Inc Company profile
Par FibroGen, Inc
FibroGen, Inc. ir biofarmācijas uzņēmums. Uzņēmums nodarbojas ar pirmās klases terapeitisko līdzekļu atklāšanu, izstrādi un komercializāciju. Uzņēmums izmanto savas spējas hipoksiju inducējošā faktora (HIF) bioloģijā, 2-oksoglutarāta enzimoloģijā un saistaudu augšanas faktora (CTGF) bioloģijā, lai izstrādātu zāles anēmijas, fibrozes slimību un vēža ārstēšanai. Uzņēmuma produkts Roxadustat ir iekšķīgi lietojams mazmolekulārs HIF-prolilhidroksilāzes (HIF-PH) aktivitātes inhibitors, kas paredzēts hronisku nieru slimību (CKD) izraisītas anēmijas ārstēšanai. Uzņēmums izstrādā Roxadustat arī ar mielodisplastiskajiem sindromiem (MDS) saistītas anēmijas ārstēšanai. Uzņēmums izstrādā arī Roxadustat ķīmijterapijas izraisītas anēmijas (CIA) ārstēšanai. Pamrevlumabs, pret CTGF vērsta cilvēka monoklonāla antiviela idiopātiskas plaušu fibrozes (IPF), lokāli progresējoša neārstējama aizkuņģa dziedzera vēža (LAPC) un Dišēna muskuļu distrofijas (DMD) ārstēšanai.
| Industry: | Biotechnology & Medical Research (NEC) |
409 Illinois Street
SAN FRANCISCO
CALIFORNIA 94158
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 530 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com